keyword
MENU ▼
Read by QxMD icon Read
search

Adalimumab in pediatrics

keyword
https://www.readbyqxmd.com/read/28434894/-a-real-world-study-focused-on-the-effectiveness-and-safety-of-adalimumab-as-first-line-anti-tnf-treatment-for-pediatric-crohn-s-disease
#1
Víctor Manuel Navas-López, Gemma Pujol Muncunill, Enrique Llerena, María Navalón Rubio, David Gil-Ortega, Vicente Varea-Calderón, Carlos Sierra Salinas, Javier Martin-de-Carpi
BACKGROUND AND OBJECTIVES: Adalimumab (ADA), a monoclonal humanised anti-TNF antibody, is usually prescribed as a second-line treatment in paediatric Crohn's disease (CD) patients who have become unresponsive or developed intolerance to infliximab (IFX). In the case series reported, more than 70% of patients had initially been treated with IFX. Data on short- and long-term effectiveness of ADA in anti-TNF naïve patients is limited. The aim of this study is to describe our experience with ADA as a first-line anti-TNF in paediatric CD patients...
April 20, 2017: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
https://www.readbyqxmd.com/read/28301428/growth-improvement-with-adalimumab-treatment-in-children-with-moderately-to-severely-active-crohn-s-disease
#2
Thomas D Walters, William A Faubion, Anne M Griffiths, Robert N Baldassano, Johanna Escher, Frank M Ruemmele, Jeffrey S Hyams, Andreas Lazar, Samantha Eichner, Bidan Huang, Yao Li, Roopal B Thakkar
BACKGROUND: Growth failure is common in children with Crohn's disease. The effect of adalimumab (ADA), a fully human antitumor necrosis factor antagonist, on height velocity in pediatric patients with baseline (BL) linear growth impairment in the IMAgINE 1 trial is presented. METHODS: This analysis included female and male patients with growth potential (bone age ≤13 and ≤14 yr, respectively), with BL Pediatric Crohn's disease Activity Index >30, and who failed or were intolerant to conventional therapy...
March 15, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28245034/biologiska-l%C3%A3-kemedel-etablerad-terapi-f%C3%A3-r-barn-med-ibd-i-sverige
#3
Magnus Svensson, Eva Lindberg, Jonas F Ludvigsson
Biological treatments in pediatric IBD In Sweden, there are an estimated 1 500 pediatric IBD patients. We sent out a survey regarding the use of biological treatments in pediatric IBD to pediatric gastroenterologists in Sweden. Of 1 098 recorded IBD patients, 17% had ongoing treatment with biological drugs. The drugs used were almost exclusively infliximab and adalimumab, i.e. anti-TNF-alpha. Use of biologics varied among responders. Anaphylactic reactions and other types of infusion reactions were the most frequent side effects...
February 21, 2017: Läkartidningen
https://www.readbyqxmd.com/read/28211161/psoriasis-and-psoriasiform-eruptions-in-pediatric-patients-with-inflammatory-bowel-disease-treated-with-anti-tumor-necrosis-factor-alpha-agents
#4
Joshua B Eickstaedt, Luke Killpack, Jeanne Tung, Dawn Davis, Jennifer L Hand, Megha M Tollefson
BACKGROUND: Anti-tumor necrosis factor alpha (TNF-α) agents are used to treat a variety of autoimmune and inflammatory conditions, including psoriasis. Paradoxically, numerous reports have documented new-onset or exacerbation of psoriasis or psoriasiform skin lesions (PSO) in patients treated with these agents for conditions other than PSO-particularly in adults with inflammatory bowel disease (IBD). Not much is known regarding similar cases in children. METHODS: A retrospective chart review was performed on children younger than 19 years of age with IBD seen at the Mayo Clinic between 2003 and 2015 who developed new-onset or recurrent PSO while undergoing anti-TNF-α therapy...
February 17, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28172657/op025-evaluation-of-adalimumab-effectiveness-in-anti-tumor-necrosis-factor-na%C3%A3-ve-pediatric-patients-with-crohn-s-disease-in-clinical-practice
#5
S Steiner, E King, K Park, D Pashankar, H Shashidhar, B Sudel, S Eichner, S Chen, J Pratt, R Colletti
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28140700/adalimumab-for-the-treatment-of-uveitis
#6
Kara C LaMattina, Debra A Goldstein
Adalimumab, an inhibitor of tumor necrosis factor-alpha (TNFα), is the only systemic non-corticosteroid agent which has been approved by the US Food and Drug Administration (FDA) for the treatment of non-infectious uveitis. Areas covered:The aim of this review is to summarize the research which demonstrated the effectiveness of adalimumab in the treatment of intraocular inflammation and helped to establish its side effect profile, ultimately leading to its FDA approval. Expert commentary:Adalimumab is a useful second-line agent in the treatment of non-infectious uveitis...
January 31, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28129288/long-term-efficacy-and-safety-of-adalimumab-in-pediatric-patients-with-crohn-s-disease
#7
William A Faubion, Marla Dubinsky, Frank M Ruemmele, Johanna Escher, Joel Rosh, Jeffrey S Hyams, Samantha Eichner, Yao Li, Nattanan Reilly, Roopal B Thakkar, Anne M Robinson, Andreas Lazar
BACKGROUND: IMAgINE 1 assessed 52-week efficacy and safety of adalimumab in children with moderate to severe Crohn's disease. Long-term efficacy and safety of adalimumab for patients who entered the IMAgINE 2 extension are reported. METHODS: Patients who completed IMAgINE 1 could enroll in IMAgINE 2. Endpoints assessed from weeks 0 to 240 of IMAgINE 2 were Pediatric Crohn's Disease Activity Index remission (Pediatric Crohn's Disease Activity Index ≤ 10) and response (Pediatric Crohn's Disease Activity Index decrease ≥15 from IMAgINE 1 baseline) using observed analysis and hybrid nonresponder imputation (hNRI)...
March 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28119823/pilot-study-of-the-safety-and-effect-of-adalimumab-on-pain-physical-function-and-musculoskeletal-disease-in-mucopolysaccharidosis-types-i-and-ii
#8
Lynda E Polgreen, Alicia Kunin-Batson, Kyle Rudser, Richard K Vehe, Jeanine J Utz, Chester B Whitley, Patricia Dickson
Mucopolysaccharidosis I and II are lysosomal storage disorders that, despite treatment with hematopoietic cell transplantation (HCT) and/or enzyme replacement therapy (ERT), continue to cause significant skeletal abnormalities leading to pain, stiffness, physical dysfunction, and short stature. Tumor necrosis factor - alpha (TNF-α) is elevated in individuals with MPS I and II and associated with pain and physical dysfunction. Therefore, we evaluated the safety and effects of the TNF-α inhibitor adalimumab in patients with MPS I and II in a 32-week, randomized, double blind, placebo-controlled, crossover study of adalimumab at a dose of 20 mg (weight 15-<30 kg) or 40 mg (weight ≥ 30 kg) administered subcutaneously every other week or saline placebo for 16 weeks...
March 2017: Molecular Genetics and Metabolism Reports
https://www.readbyqxmd.com/read/27900937/post-authorization-changes-in-the-safety-and-efficacy-assessment-recommended-indications-and-drug-quality-profile-of-adalimumab-a-chronological-overview
#9
Gergely Iványi, Romána Zelkó
OBJECTIVE: The intention of the present study was to demonstrate the postauthorization changes of adalimumab (European trade name: Humira), evaluating the variations in its safety, efficacy, and quality profile. METHODS: Type-II, major variations of the Summary of Product Characteristics (SmPC) from September 8, 2003 to November 19, 2015, were analyzed, which, according to Commission Regulation (EC) No. 1234/2008, have to reflect changes that may have a significant impact on the safety, efficacy, or quality profile of a medicinal product...
February 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27881144/comparison-of-treatment-response-remission-rate-and-drug-adherence-in-polyarticular-juvenile-idiopathic-arthritis-patients-treated-with-etanercept-adalimumab-or-tocilizumab
#10
Gerd Horneff, Ariane Klein, Jens Klotsche, Kirsten Minden, Hans-Iko Huppertz, Frank Weller-Heinemann, Jasmin Kuemmerle-Deschner, Johannes-Peter Haas, Anton Hospach
BACKGROUND: Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice. METHODS: Data collected in the German BIKER registry were analyzed in patients with polyJIA who started treatment with approved biologics, adalimumab, etanercept or tocilizumab, from 2011 to 2015. Baseline patient characteristics, treatment response, safety and drug survival were compared...
November 24, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27832822/sarcoidosis-presenting-as-granulomatous-myositis-in-a-16-year-old-adolescent
#11
Amir B Orandi, Eric Eutsler, Cole Ferguson, Andrew J White, Maleewan Kitcharoensakkul
BACKGROUND: Sarcoidosis is a multi-system disease characterized by the presence of non-caseating epithelioid granulomas in affected tissues, including skeletal muscle. These organized collections of immune cells have important pathophysiologic action including cytokine production leading to inflammation as well as enzymatic conversion of cholecalciferol to calcitriol via 1-α hydroxylase. There are limited reports of isolated granulomatous myositis causing hypercalcemia in pediatric patients...
November 10, 2016: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/27800265/treatment-of-juvenile-idiopathic-arthritis-associated-uveitis
#12
REVIEW
Merih Oray, İlknur Tuğal-Tutkun
Pediatric uveitis may be a serious health problem because of the lifetime burden of vision loss due to severe complications if the problem is not adequately treated. Juvenile idiopathic arthritis (JIA)-associated uveitis is characterized by insidious onset and potentially blinding chronic anterior uveitis. Periodic ophthalmologic screening is of utmost importance for early diagnosis of uveitis. Early diagnosis and proper immunomodulatory treatment are essential for good visual prognosis. The goal of treatment is to achieve enduring drug-free remission...
April 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/27766695/invasive-fungal-infections-in-pediatric-patients-treated-with-tumor-necrosis-alpha-tnf-%C3%AE-inhibitors
#13
REVIEW
Athanasios Tragiannidis, Ioannis Kyriakidis, Ilse Zündorf, Andreas H Groll
Macromolecular immunosuppressive monoclonal antibodies and fusion proteins directed against molecules or cells involved in inflammation and immunity represent a recent and important addition to our therapeutic armamentarium. Tumor necrosis alpha (TNFα) is a cytokine involved in systemic inflammation and clinical utilization of its antagonists has revolutionized treatment of juvenile rheumatoid and psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Clinical utility has also been demonstrated for use against steroid-refractory graft-vs-host disease and other immune-mediated conditions...
April 2017: Mycoses
https://www.readbyqxmd.com/read/27749657/disseminated-tuberculosis-resulting-from-reinfection-in-a-pediatric-patient-sequentially-treated-with-etanercept-and-adalimumab
#14
Carmelo Guerrero-Laleona, Joan Calzada-Hernández, Matilde Bustillo-Alonso, Jorge Gil-Albarova, Marta Medrano-San Ildefonso, Estibaliz Iglesias-Jiménez, Antoni Noguera-Julian
Treatment with tumor necrosis factor α inhibitors is a risk factor for tuberculosis (TB). Despite previous treatment with isoniazid for latent TB, a 9-year-old girl with juvenile idiopathic arthritis developed disseminated TB after changing therapy with etanercept to adalimumab and after new contact with a smear-positive relative. Genotyping strain matches and susceptibility to isoniazid make reinfection more likely than reactivation in our patient.
January 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27636407/biological-therapy-in-pediatric-inflammatory-bowel-disease-a-systematic-review
#15
Domenico Corica, Claudio Romano
The incidence of inflammatory bowel disease (IBD) has increased steadily worldwide, both in adult and in children; approximately 25% of IBD patients are diagnosed before the age of 18. The natural history of IBD is usually more severe in children than in adults, and can be associated with linear growth impairment, delayed puberty onset, reduced bone mass index, malnutrition, and the need for surgery. Biological therapies, especially blocking tumor necrosis factor-α (TNFα), have radically modified the treatment strategies and disease course of IBD in children...
February 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/27478130/the-treatment-with-infliximab-for-pediatric-crohn-s-disease-nationwide-survey-of-japan
#16
Kenji Hosoi, Yoshikazu Ohtsuka, Tohru Fujii, Takahiro Kudo, Nobuaki Matsunaga, Takeshi Tomomasa, Hitoshi Tajiri, Reiko Kunisaki, Takashi Ishige, Hiroyuki Yamada, Katsuhiro Arai, Atsushi Yoden, Kosuke Ushijima, Tomoki Aomatsu, Satoru Nagata, Keiichi Uchida, Kazuo Takeuchi, Toshiaki Shimizu
BACKGROUND: Childhood-onset inflammatory bowel disease (IBD) is characterized by extensive intestinal involvement and rapid early progression. Infliximab (IFX), cyclosporine (CYA), and tacrolimus (FK506) are increasingly used to treat pediatric IBD; however, their long-term effects and adverse events have not been properly investigated in pediatric patients. The aim of this study was to characterize the effects of these biologics and immunomodulators on pediatric IBD patients in Japan...
July 31, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27462478/biologics-and-pediatric-generalized-pustular-psoriasis-an-emerging-therapeutic-trend
#17
REVIEW
Sami K Saikaly, Monica Mattes
Generalized pustular psoriasis (GPP) is a rare form of childhood psoriasis, often requiring systemic therapy, which is challenging as there is a paucity of randomized controlled trials and standardized guidelines. Biologic agents have been used in adults and in pediatric plaque psoriasis, but evidence regarding their efficacy in pediatric GPP has slowly become available. The objective of this study is to summarize and compare the efficacy and safety of biologic agents, such as etanercept, infliximab, and adalimumab, in the treatment of pediatric GPP...
June 22, 2016: Curēus
https://www.readbyqxmd.com/read/27437188/adalimumab-treatment-in-pediatric-onset-crohn-s-disease-patients-after-infliximab-failure-a-single-center-study
#18
Won Jae Song, Ben Kang, So Yoon Choi, Yon Ho Choe
PURPOSE: We aimed to investigate the efficacy and safety of adalimumab in pediatric-onset Crohn's disease patients who had failed treatment with infliximab. METHODS: In this retrospective study, patients included were those who had been diagnosed with Crohn's disease before 18 years old, and had received treatment with adalimumab after infliximab failure. The efficacy of adalimumab treatment was investigated at 1 month and 1 year, and adverse events that had occurred during treatment with adalimumab were explored...
June 2016: Pediatric Gastroenterology, Hepatology & Nutrition
https://www.readbyqxmd.com/read/27363233/advances-in-pediatric-inflammatory-bowel-disease
#19
REVIEW
Elizabeth C Maxwell, Andrew B Grossman
No abstract text is available yet for this article.
2016: Adolescent Medicine: State of the Art Reviews
https://www.readbyqxmd.com/read/27135404/the-clinical-effectiveness-and-cost-effectiveness-of-abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis-a-systematic-review-and-economic-evaluation
#20
Jonathan Shepherd, Keith Cooper, Petra Harris, Joanna Picot, Micah Rose
BACKGROUND: Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and a limitation of movement caused by inflammation. Subsequent joint damage can lead to disability and growth restriction. Treatment commonly includes disease-modifying antirheumatic drugs (DMARDs), such as methotrexate. Clinical practice now favours newer drugs termed biologic DMARDs where indicated. OBJECTIVE: To assess the clinical effectiveness and cost-effectiveness of four biologic DMARDs [etanercept (Enbrel(®), Pfizer), abatacept (Orencia(®), Bristol-Myers Squibb), adalimumab (Humira(®), AbbVie) and tocilizumab (RoActemra(®), Roche) - with or without methotrexate where indicated] for the treatment of JIA (systemic or oligoarticular JIA are excluded)...
April 2016: Health Technology Assessment: HTA
keyword
keyword
115702
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"